0001493152-26-007052
SEC filingPropanc Biopharma, Inc. (PPCB) reported a net loss of $4.0M for Q2 2026 ending December 31, 2025, including a $932K deemed dividend on Series C Preferred Stock, compared to a $3.1M loss before the dividend. The company generated no revenue, with total operating expenses of $3.7M driven primarily by $3.6M in administration expenses, resulting in an operating loss of $3.7M. Other income of $563K, mainly from a $594K favorable change in warrant liability, partially offset losses, leading to a pre-tax loss of $3.1M. Balance sheet shows total assets of $15.1M, including $7.7M current assets with $561K cash and $7.1M prepaid expenses (current portion). Total liabilities stand at $3.7M, with stockholders' equity negative at -$3.8M due to $134.5M accumulated deficit. Cash increased by $549K to $561K, driven by $3.5M net financing inflows from $3.3M common stock sales and $950K Series C preferred stock, offsetting $217K operating cash use. No prior period comparisons disclosed in filing.
Propanc Biopharma, Inc. reported a comprehensive loss of $4.0M for the quarter ended December 31, 2025, consistent with net loss after a $932K deemed dividend on Series C Convertible Preferred Stock. Loss from operations was $3.7M driven by $3.6M administration expenses, $20K research and development, and $7K occupancy expenses (related party), with no revenue recognized. Other income netted $563K, primarily from -$594K change in fair value of warrant liability, $88K change in derivative liabilities, offset by $59K interest expense and other items. Loss before taxes was $3.1M. Basic and diluted net loss per share was -$0, with 13.4M weighted average shares outstanding. Total comprehensive loss included -$8K unrealized foreign currency translation loss. No prior quarter or year comparisons provided in the XBRL data.
No revenue was reported for the quarter ended December 31, 2025. The Income Statement shows Revenue: N/A across all categories. As a biopharma development-stage company, Propanc Biopharma has not yet commercialized products, focusing on research and administrative activities without product sales or licensing revenue disclosed.
Not applicable due to absence of revenue. Operating loss of $3.7M on zero revenue reflects full cost absorption. Key expenses include administration at $3.6M (97% of total operating expenses), research and development $20K, and related-party occupancy $7K. Non-operating items improved profitability with $563K net other income, reducing pre-tax loss to $3.1M before the $932K deemed dividend increased net loss to $4.0M. No margin metrics calculable.
Net cash used in operating activities was $217K, adjusted from $3.1M net loss by $5.5M prepaid stock amortization, $734K stock for services, and -$594K warrant liability change. Investing used $5K for equipment. Financing provided $3.5M, including $3.3M common stock sales, $950K Series C preferred stock, offset by $672K note repayments and $203K convertible note repayments. Cash rose $549K to $561K. Balance sheet: $15.1M total assets ($7.7M current, including $7.1M prepaid current), $3.7M liabilities ($3.6M current), $1.0M temporary equity (Series C Preferred, 100 shares outstanding, $1M liquidation value), -$3.8M stockholders' equity (-$134.5M accumulated deficit). Liquidity supported by financing.
No management guidance, strategic priorities, or risk factors explicitly disclosed in the provided XBRL financial data or document content. Commitments and contingencies referenced in Note 9, but no details provided.